The Cook Zilver PTX Drug-eluting Stent Versus Bypass Surgery for the Treatment of Femoropopliteal TASC C&D Lesions (ZILVERPASS).

Trial Profile

The Cook Zilver PTX Drug-eluting Stent Versus Bypass Surgery for the Treatment of Femoropopliteal TASC C&D Lesions (ZILVERPASS).

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 17 Jan 2017

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Peripheral artery restenosis; Peripheral vascular disorders
  • Focus Therapeutic Use
  • Acronyms ZILVERPASS
  • Most Recent Events

    • 11 Jan 2017 Planned End Date changed from 1 Nov 2017 to 1 Sep 2017.
    • 11 Jan 2017 Planned primary completion date changed from 1 Sep 2016 to 1 Sep 2017.
    • 05 Aug 2014 Planned End Date changed from 1 Nov 2016 to 1 Nov 2017 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top